Key facts
- LYEL - Lyell Immunopharma, Inc. has 25 insiders with reported activity on this page.
- Net insider value flow over the last year: +$24,513,700.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 25 Insiders of Lyell Immunopharma, Inc.
- Symbol
- LYEL on Nasdaq
- Location
- South San Francisco, CA
Change
- Buy value: $24,999,970; sell value: $486,269.
- Net share flow: +949,231.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$24,513,700.
Buys
$24,999,970
Shares: 976,180
Insiders: 2
Sells
$486,269
Shares: 26,949
Insiders: 5
Net
+$24,513,700
Shares: +949,231
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 976,180 | 0 | $24,999,970 | $0 | +$24,999,970 |
| 3-6 | 0 | 13,382 | $0 | $338,466 | -$338,466 |
| 6-9 | 0 | 884 | $0 | $14,247 | -$14,247 |
| 9-12 | 0 | 12,683 | $0 | $133,557 | -$133,557 |
Lyell Immunopharma, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert Nelsen | Director, 10%+ Owner | $83,020,992 | Mixed | 14 Jun 2024 | ||
| GSK plc | 10%+ Owner | $68,977,271 | Mixed | 21 Jun 2021 | ||
| ARCH Venture Partners IX, LLC | 10%+ Owner | $36,533,382 | +$12,499,985 | +52% | Filing P/S | 06 Mar 2026 |
| ARCH Venture Fund XIII, L.P. | 10%+ Owner | $36,533,382 | +$12,499,985 | +52% | Filing P/S | 06 Mar 2026 |
| Hans Edgar Bishop | Director | $10,683,200 | Mixed | 14 Jun 2024 | ||
| Richard Klausner | Director | $1,791,262 | Mixed | 15 May 2025 | ||
| Lynn Seely | President and CEO, Director | $1,737,081 | -$275,967 | -14% | Filing P/S | 11 Feb 2026 |
| David Shook | Chief Medical Officer | $519,249 | Mixed | 10 Feb 2026 | ||
| Stephen J. Hill | Chief Operating Officer | $416,225 | -$45,477 | -9.8% | Filing P/S | 11 Feb 2026 |
| Gary K. Lee | Chief Scientific Officer | $396,179 | -$62,819 | -14% | Filing P/S | 11 Feb 2026 |
| Veronica Sanchez Bulis | VP, Corporate Controller | $361,527 | -$83,901 | -19% | Filing P/S | 10 Feb 2026 |
| Charles W. Newton | Chief Financial Officer | $290,086 | -$18,105 | -5.9% | Mixed | 20 Aug 2025 |
| Cathy Friedman | Director | $158,093 | Mixed | 15 May 2025 | ||
| Matthew Lang | Chief Business Officer | $114,000 | Mixed | 10 Feb 2025 | ||
| Sumant Ramachandra | Director | $94,000 | Mixed | 15 May 2025 | ||
| Dr. Otis W. Brawley | Director | $16,750 | Mixed | 15 May 2025 | ||
| Tina M. Albertson | Chief Medical Officer | $9,232 | Mixed | 24 Feb 2023 | ||
| Mark Bachleda | Director | Mixed | 09 Jun 2025 | |||
| Mark A. Meltz | General Counsel | Mixed | 10 Feb 2026 | |||
| Rahsaan W. Thompson | Chief Legal Officer | Mixed | 24 Feb 2023 | |||
| Smital Shah | Chief Fin. and Bus. Officer | Mixed | 09 Mar 2026 | |||
| Elizabeth Homans | Chief Executive Officer, Director | Mixed | 16 Mar 2022 | |||
| William Jl Rieflin | Director | Mixed | 15 May 2025 | |||
| Elizabeth G. Nabel | Director | Mixed | 15 May 2025 | |||
| Heather D. Turner | Chief General Counsel | Mixed | 16 Mar 2022 |
Top shareholders of Lyell Immunopharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. |
13D/G
|
— |
14%
|
3,247,162
|
$65,138,070 | -$669,012,113 | 31 Mar 2026 | |
| Innovative Cellular Therapeutics Holdings Ltd |
13D/G
|
— |
9.8%
|
1,900,000
|
$30,855,810 | $0 | 06 Nov 2025 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
7.6%
|
1,454,616
|
$23,622,818 | $0 | 30 Sep 2025 | |
| Euler Fund, L.P. |
13D/G
|
— |
6.7%
|
1,426,528
|
$43,908,532 | $0 | 06 Mar 2026 | |
| Explore Investments LLC/DE |
13D/G
|
Explore Investments LLC |
6.6%
|
1,529,054
|
$47,064,282 | +$15,023,410 | 31 Mar 2026 | |
| Gates Frontier, LLC |
13D/G
|
— |
5.6%
|
1,040,964
|
$10,628,242 | $0 | 25 Jul 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
4.5%
|
13,265,869
|
$6,234,958 | $0 | 31 Dec 2024 | |
| MWG Caph Ltd |
13D/G
|
— |
4.3%
|
1,008,116
|
$31,029,810 | $0 | 31 Mar 2026 | |
| NEWTON (PTC) Ltd |
13D/G
|
Newton (PTC) Limited |
3.9%
|
754,698
|
$12,256,220 | $0 | 30 Sep 2025 | |
| ARCH Venture Fund XIII, L.P. |
3/4/5
|
10%+ Owner |
7.5%
|
1,426,528
|
$36,533,382 | +$12,499,985 | 06 Mar 2026 | |
| ARCH Venture Partners IX, LLC |
3/4/5
|
10%+ Owner |
7.5%
|
1,426,528
|
$36,533,382 | +$12,499,985 | 06 Mar 2026 | |
| Veronica Sanchez Bulis |
3/4/5
|
VP, Corporate Controller |
0.08%
|
15,637
|
$361,527 | -$83,901 | 10 Feb 2026 | |
| ARCH Venture Management, LLC |
13F
|
Company |
17%
|
3,247,162
|
$65,138,070 | — | 31 Mar 2026 | |
| GSK plc |
3/4/5
13F
|
10%+ Owner · Company |
7.9%
from 13F
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
4.2%
|
800,399
|
$16,056,004 | — | 31 Mar 2026 | |
| Orland Properties Ltd |
13F
|
Company |
3.9%
|
754,698
|
$15,139,242 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.8%
|
718,155
|
$14,406,189 | — | 31 Mar 2026 | |
| Almitas Capital LLC |
13F
|
Company |
3%
|
577,807
|
$11,590,808 | — | 31 Mar 2026 | |
| Decheng Capital LLC |
13F
|
Company |
3%
|
692,050
|
$13,882,523 | — | 31 Mar 2026 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
2.5%
|
477,078
|
$9,570,185 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.4%
|
458,905
|
$9,205,634 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2%
|
381,462
|
$7,652,128 | — | 31 Mar 2026 | |
| venBio Partners LLC |
13F
|
Company |
1.8%
|
337,697
|
$6,774,202 | — | 31 Mar 2026 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.6%
|
310,198
|
$6,222,572 | — | 31 Mar 2026 | |
| Alphabet Inc. |
13F
|
Company |
1.5%
|
293,256
|
$5,882,715 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.87%
|
166,980
|
$3,351,556 | — | 31 Mar 2026 | |
| HSG Holding Ltd |
13F
|
Company |
0.8%
|
152,299
|
$73,104 | — | 31 Mar 2026 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.78%
|
148,516
|
$2,979,230 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.61%
|
116,411
|
$2,335,205 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.6%
|
114,491
|
$2,296,689 | — | 31 Mar 2026 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.53%
|
102,000
|
$2,046,120 | — | 31 Mar 2026 | |
| MIC Capital Management UK LLP |
13F
|
Company |
0.45%
|
87,028
|
$1,745,782 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.45%
|
86,925
|
$1,743,716 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.45%
|
85,971
|
$1,724,578 | — | 31 Mar 2026 | |
| Opaleye Management Inc. |
13F
|
Company |
0.41%
|
79,097
|
$1,586,686 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
0.38%
|
72,522
|
$1,454,791 | — | 31 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.33%
|
63,893
|
$1,281,694 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.29%
|
56,151
|
$1,126,389 | — | 31 Mar 2026 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.29%
|
55,110
|
$1,105,507 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.25%
|
47,888
|
$958,999 | — | 31 Mar 2026 | |
| RBF Capital, LLC |
13F
|
Company |
0.23%
|
44,094
|
$884,526 | — | 31 Mar 2026 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.21%
|
41,081
|
$824,084 | — | 31 Mar 2026 | |
| Clearstead Advisors, LLC |
13F
|
Company |
0.21%
|
39,916
|
$800,715 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.17%
|
33,321
|
$668,420 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.17%
|
31,814
|
$638,188 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.16%
|
30,280
|
$607,417 | — | 31 Mar 2026 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
0.15%
|
29,411
|
$589,985 | — | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
0.12%
|
23,015
|
$461,681 | — | 31 Mar 2026 | |
| Walleye Capital LLC |
13F
|
Company |
0.12%
|
22,207
|
$445,472 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.11%
|
21,292
|
$427,118 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Lyell Immunopharma, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Smital Shah | LYEL | Option (right to buy) | Award | 140,000 | 140,000 | 09 Mar 2026 | Direct | |||
| ARCH Venture Partners IX, LLC | LYEL | Common Stock | Purchase | 52% | $12,499,985 | $25.61 | 488,090 | 1,426,528 | 06 Mar 2026 | See footnote |
| ARCH Venture Fund XIII, L.P. | LYEL | Common Stock | Purchase | 52% | $12,499,985 | $25.61 | 488,090 | 1,426,528 | 06 Mar 2026 | See footnote |
| Lynn Seely | LYEL | Common Stock | Sale | -9.12% | $174,372 | $23.39 | -7,455 | 74,266 | 11 Feb 2026 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -6.49% | $28,910 | $23.39 | -1,236 | 17,795 | 11 Feb 2026 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -8.98% | $39,085 | $23.39 | -1,671 | 16,938 | 11 Feb 2026 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -0.57% | $2,520 | $23.12 | -109 | 19,031 | 10 Feb 2026 | Direct |
| Stephen J. Hill | LYEL | Option (right to buy) | Award | 65,000 | 65,000 | 10 Feb 2026 | Direct | |||
| Gary K. Lee | LYEL | Common Stock | Sale | -0.78% | $3,399 | $23.12 | -147 | 18,609 | 10 Feb 2026 | Direct |
| Gary K. Lee | LYEL | Option (right to buy) | Award | 50,000 | 50,000 | 10 Feb 2026 | Direct | |||
| Lynn Seely | LYEL | Common Stock | Sale | -0.53% | $10,127 | $23.12 | -438 | 81,721 | 10 Feb 2026 | Direct |
| Lynn Seely | LYEL | Option (right to buy) | Award | 155,000 | 155,000 | 10 Feb 2026 | Direct | |||
| Mark A. Meltz | LYEL | Option (right to buy) | Award | 50,000 | 50,000 | 10 Feb 2026 | Direct | |||
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -1.6% | $5,872 | $23.12 | -254 | 15,637 | 10 Feb 2026 | Direct |
| Veronica Sanchez Bulis | LYEL | Common Stock | Award | 122.5% | 8,750 | 15,891 | 10 Feb 2026 | Direct | ||
| David Shook | LYEL | Option (right to buy) | Award | 50,000 | 50,000 | 10 Feb 2026 | Direct | |||
| Stephen J. Hill | LYEL | Common Stock | Award | 26.4% | 4,000 | 19,140 | 09 Feb 2026 | Direct | ||
| Gary K. Lee | LYEL | Common Stock | Award | 27.1% | 4,000 | 18,756 | 09 Feb 2026 | Direct | ||
| Lynn Seely | LYEL | Common Stock | Award | 32.2% | 20,000 | 82,159 | 09 Feb 2026 | Direct | ||
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -11.6% | $30,252 | $32.32 | -936 | 7,141 | 30 Dec 2025 | Direct |
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -12.3% | $43,929 | $38.67 | -1,136 | 8,077 | 24 Dec 2025 | Direct |
| Veronica Sanchez Bulis | LYEL | Common Stock | Sale | -2.53% | $3,848 | $16.10 | -239 | 9,213 | 10 Nov 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -0.89% | $2,230 | $16.16 | -138 | 15,366 | 10 Nov 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -0.6% | $1,531 | $16.12 | -95 | 15,750 | 10 Nov 2025 | Direct |
| Lynn Seely | LYEL | Common Stock | Sale | -0.61% | $6,637 | $16.11 | -412 | 67,159 | 10 Nov 2025 | Direct |
| Stephen J. Hill | LYEL | Option (right to buy) | Award | 75,000 | 75,000 | 27 Oct 2025 | Direct | |||
| Gary K. Lee | LYEL | Option (right to buy) | Award | 68,000 | 68,000 | 27 Oct 2025 | Direct | |||
| Lynn Seely | LYEL | Option (right to buy) | Award | 175,000 | 175,000 | 27 Oct 2025 | Direct | |||
| Lynn Seely | LYEL | Common Stock | Sale | -9.7% | $76,518 | $10.54 | -7,257 | 67,571 | 21 Aug 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -5.96% | $10,586 | $10.54 | -1,004 | 15,845 | 21 Aug 2025 | Direct |
| Charles W. Newton | LYEL | Common Stock | Sale | -8.67% | $15,320 | $10.54 | -1,453 | 15,306 | 21 Aug 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -8.57% | $15,320 | $10.54 | -1,453 | 15,504 | 21 Aug 2025 | Direct |
| Lynn Seely | LYEL | Common Stock | Award | 114.8% | 40,000 | 74,828 | 20 Aug 2025 | Direct | ||
| Stephen J. Hill | LYEL | Common Stock | Award | 90.4% | 8,000 | 16,849 | 20 Aug 2025 | Direct | ||
| Charles W. Newton | LYEL | Common Stock | Award | 91.3% | 8,000 | 16,759 | 20 Aug 2025 | Direct | ||
| Gary K. Lee | LYEL | Common Stock | Award | 89.3% | 8,000 | 16,957 | 20 Aug 2025 | Direct | ||
| Lynn Seely | LYEL | Common Stock | Sale | -1.15% | $4,197 | $10.34 | -406 | 34,828 | 12 Aug 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -1.05% | $972 | $10.34 | -94 | 8,849 | 12 Aug 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -1.5% | $1,406 | $10.34 | -136 | 8,957 | 12 Aug 2025 | Direct |
| Charles W. Newton | LYEL | Common Stock | Sale | -1.53% | $1,406 | $10.34 | -136 | 8,759 | 12 Aug 2025 | Direct |
| Lynn Seely | LYEL | Common Stock | Sale | -1.1% | $4,116 | $10.53 | -391 | 35,234 | 11 Aug 2025 | Direct |
| Stephen J. Hill | LYEL | Common Stock | Sale | -1.01% | $958 | $10.53 | -91 | 8,943 | 11 Aug 2025 | Direct |
| Gary K. Lee | LYEL | Common Stock | Sale | -1.42% | $1,379 | $10.53 | -131 | 9,093 | 11 Aug 2025 | Direct |
| Charles W. Newton | LYEL | Common Stock | Sale | -1.45% | $1,379 | $10.53 | -131 | 8,895 | 11 Aug 2025 | Direct |
| Mark Bachleda | LYEL | Option (right to buy) | Award | 13,000 | 13,000 | 09 Jun 2025 | Direct | |||
| Mark A. Meltz | LYEL | Option (right to buy) | Award | 100,000 | 100,000 | 09 Jun 2025 | Direct | |||
| David Shook | LYEL | Common Stock | Award | 21,900 | 21,900 | 09 Jun 2025 | Direct | |||
| David Shook | LYEL | Option (right to buy) | Award | 43,750 | 43,750 | 09 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.